secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-241705
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M
------------------------------------------------------------------------------

- CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.
- Board member Jan Reed appointed Lead Independent Director; search for permanent CEO commenced.
- Preliminary Q3 2025 revenue expected ~$17M; company to provide update on Nov 6 earnings call.
- OrbiMed waived Q3 2025 trailing 12-month net revenue covenant; discussions underway to redefine future covenants.
- Departure not due to any disagreement with the company on operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312525241705/0001193125-25-241705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312525241705/rcel-20251016.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-241705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer